Once-weekly IcoSema versus Daily Insulin Glargine U100 in Type 2 Diabetes: Evidence from the COMBINE 4 Phase 3b Trial and Related Advances
Posted inClinical Updates Diabetes & Endocrinology news

Once-weekly IcoSema versus Daily Insulin Glargine U100 in Type 2 Diabetes: Evidence from the COMBINE 4 Phase 3b Trial and Related Advances

COMBINE 4 demonstrated that once-weekly IcoSema (icodec+semaglutide) offers superior glycemic control, weight reduction, and reduced hypoglycemia versus daily insulin glargine U100 in insulin-naive type 2 diabetes patients, supported by complementary phase 3 studies on insulin icodec.
High-Intensity Interval Exercise in Type 1 Diabetes: Stronger Protection Against Exercise-Related Glycaemic Decline in the Postabsorptive Than Postprandial State
Posted inClinical Updates news

High-Intensity Interval Exercise in Type 1 Diabetes: Stronger Protection Against Exercise-Related Glycaemic Decline in the Postabsorptive Than Postprandial State

This clinical update reviews a new randomized crossover trial and prior literature showing that high-intensity interval exercise can attenuate glucose decline and late hypoglycaemia in adults with type 1 diabetes, particularly when performed in the postabsorptive state.